Drug intelligence / Profile preview

LM-350

Development stage: Phase 2
Lead developer: LaNova Medicines
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

LM-350 is a **CDH17-targeted antibody-drug conjugate (ADC)** designed to treat malignancies such as colorectal cancer and gastric (stomach) cancer. It consists of an antibody specific for Cadherin-17 (CDH17) linked to a cytotoxic payload that inhibits DNA topoisomerase I (TOP1), combining targeted delivery with a DNA-damaging mechanism. LM-350 is being developed by LaNova Medicines (acquired by Sino Biopharmaceutical) and is primarily being advanced for neoplasms affecting the digestive system, notably showing preclinical anti-tumor activity, including in colorectal cancer models resistant to other therapies[1][2][3][4].

Targets

CDH17 (Cadherin-17)

Beyond the preview

Go deeper on LM-350.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LM-350.

Explore the full profile